1. The Frame
What people think this is about: Joe Kiani is the Iranian immigrant success story who founded Masimo, invented reliable motion-tolerant pulse oximetry, built a public medtech company, pushed patient safety reforms, and served on Biden’s PCAST.
What the machinery is actually doing: An activist investor ousted the founder-CEO from the board in 2024 after years of stock underperformance and a disastrous consumer audio acquisition; mutual lawsuits over the proxy vote, severance, and board conduct followed, while Kiani pivoted to Willow Laboratories and collected board seats elsewhere.
2. Observations
- Kiani built real, clinically validated technology at Masimo that demonstrably reduced false alarms and improved outcomes in neonates and post-op settings; independent studies back the core SET claims (LT).
- The 2022 Sound United acquisition cratered Masimo’s market cap; the division was later sold at a steep loss after Kiani’s departure, illustrating classic founder overreach into adjacent businesses without clear synergy.
- Activist Politan won the 2024 proxy fight on performance and governance grounds; Masimo then sued Kiani and RTW for alleged vote coordination, while Kiani filed notices to sue the board—classic mutual litigation after a control contest.
- High CEO pay (including a $222M year) and stock ownership created classic alignment-plus-extraction incentives; post-ouster disputes center on whether he collects additional equity or severance packages.
- Patient safety advocacy via the Masimo Foundation and Patient Safety Movement Foundation produced measurable pledges and summits, but it also burnished a public persona that coexisted with aggressive IP defense and high executive compensation.
- As of mid-2026, Kiani remains a significant Masimo shareholder (stake valued in the hundreds of millions post-Danaher deal context) while chairing/executing at Willow and adding board roles (Scripps, others), showing rapid repositioning rather than retirement.
3. Snapshot
Joe Kiani (b. 1964) founded Masimo in 1989 after spotting limitations in existing pulse oximeters. The company went public in 2007 and grew into a major noninvasive monitoring player. In September 2024, activist investor Politan Capital won board control; Kiani resigned as CEO. Masimo sued him and RTW Investments over the shareholder vote. Kiani has since led Willow Laboratories (diabetes/wellness focus) and taken additional board seats. Masimo itself was later acquired by Danaher in a ~$10B transaction.
4. Timeline of material facts
- 1989: Kiani founds Masimo after developing motion-artifact solution (LT).
- 2007: Masimo IPO (LT).
- 2021: Appointed to Biden PCAST; co-chairs patient safety working group (LT).
- 2022: Masimo acquires Sound United audio brands for >$1B; stock drops sharply (LT).
- Sep 19, 2024: Shareholders remove Kiani from board in proxy contest; he resigns as CEO (LT).
- Late 2024–2025: Masimo sues Kiani/RTW over alleged vote manipulation; Kiani files PAGA notice against board (LT).
- 2025–2026: Masimo sells Sound United to Harman for ~$350M; Kiani joins Scripps Research board (Feb/Mar 2026) and is reported as Exec Chair at Willow (IT).
- 2026: Context of Masimo acquisition by Danaher (~$10B); Kiani remains shareholder with ongoing equity/severance disputes (IT).
5. Sides
Kiani / founder camp (IT/LT mix): Built durable clinical technology from first principles, defended patents against larger players, funded patient-safety infrastructure, and created shareholder value over decades. Claims the proxy fight and subsequent suits reflect activist short-termism and board self-dealing.
Critique: LT on core tech and safety work; IT on “activist sabotage” framing when stock performance and the audio deal provided legitimate governance concerns.
Activist investors / new board (Politan-led) (IT): Pushed accountability after prolonged underperformance and a value-destroying acquisition. Sought to separate founder from day-to-day control.
Critique: LT on documented stock reaction to audio deal and governance complaints; IT on clean “performance only” narrative when lawsuits suggest personal stakes in the transition.
Masimo as institution (post-Kiani): Prioritizes operational focus and eventual sale to Danaher.
Critique: LT on the sale outcome; DK on whether removing the founder accelerated or merely coincided with the exit.
6. Rumsfeld Matrix
- Known Knowns: Kiani founded Masimo, developed SET pulse oximetry with strong clinical evidence; lost 2024 board vote; mutual litigation ensued; Sound United deal lost substantial value.
- Known Unknowns: Exact current value of Kiani’s disputed equity/severance claims; precise terms of any Danaher-related payouts to legacy shareholders.
- Unknown Knowns: Internal board communications and voting coordination details still under litigation.
- Unknown Unknowns: Long-term performance of Willow Laboratories; whether Kiani’s patient-safety brand survives the corporate divorce.
7. Incentives map
- Kiani: Status as founder-innovator, large personal wealth tied to Masimo equity, legacy via safety foundation, new ventures at Willow.
- Activists/new board: Fees, carried interest from successful campaigns, reputational win from ousting underperforming founder, smoother path to sale.
- Media/engagement: Proxy fights, lawsuits, and “billionaire vs. activist” stories reliably generate clicks; patient-safety narrative provides softer coverage.
- Masimo post-transition: Liability management and clean narrative for the Danaher exit.
8. Dueling AI advice
Moral AI Advice: Track the lawsuits to their factual conclusions rather than narrative framing. Founder skill in one domain does not guarantee competence in capital allocation or governance; activists often improve outcomes when performance has lagged. Patient-safety work stands on its own merits separate from compensation or board fights.
Evil AI Advice: Position yourself as the indispensable visionary while extracting maximum severance and equity through prolonged litigation. Use the safety foundation for branding while the core company gets sold; collect board sinecures on the side. The second yacht funds itself.
9. Practical takeaway
- Watch the ongoing Kiani vs. Masimo/Politan litigation dockets for concrete outcomes on equity and severance.
- Distinguish Kiani’s technical and safety contributions from his record as public-company capital allocator.
- Note that activist success here followed measurable value destruction (audio deal), not abstract ideology.
- Kiani’s post-Masimo activity (Willow, boards) shows the typical founder path of new vehicles rather than exit.
- Primary sources (SEC filings, court documents) will matter more than press releases on either side.
10. What would falsify this read
- Court findings that definitively clear or condemn one side on vote manipulation or breach claims.
- Public release of internal Masimo documents showing the audio acquisition was board-approved despite known risks.
- Kiani’s Willow entity achieving independent clinical or commercial validation comparable to early Masimo.
- Evidence that the 2024 proxy outcome was driven primarily by non-performance factors.